Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JD Health International, Inc. ( (HK:6618) ) has provided an announcement.
JD Health International, Inc. announced its interim results for the first half of 2025, reporting significant financial growth with a 24.5% increase in revenue to RMB35.3 billion and a 27.4% rise in profit to RMB2.59 billion. The company has improved its healthcare offerings and advanced AI-enhanced service models, reinforcing its leading position in the healthcare market and addressing the growing demand for high-quality healthcare services. The company’s strategic focus on AI and health consumption aligns with China’s policies promoting high-quality healthcare development, further solidifying its market position.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$56.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International, Inc. operates in the healthcare industry, focusing on providing healthcare products and services. The company is known for its omnichannel model that includes direct sales, online marketplace, and on-demand retail, partnering with leading pharmaceutical companies to enhance service experiences and maintain competitive pricing.
Average Trading Volume: 8,992,967
Technical Sentiment Signal: Buy
Current Market Cap: HK$172.5B
Find detailed analytics on 6618 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money